Bromocriptine: A novel approach to the treatment of type 2 diabetes

Diabetes Care

Volumn 23, Issue 8, 2000, Pages 1154-1161

  Pijl, Hanno ^a   Ohashi, Shinichiro ^a   Matsuda, Masafumi ^a   Miyazaki, Yoshinori ^a   Mahankali, Archana ^a   Kumar, Vineeta ^a   Pipek, Ruben ^a   Iozzo, Patricia ^a   Lancaster, Jack L ^a   Cincotta, Anthony H ^b   DeFronzo, Ralph A ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Ergo Science Corp   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; GLUCOSE; HEMOGLOBIN A1C; PLACEBO;

ADULT; ARTICLE; BODY COMPOSITION; BODY FAT; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; HUMAN; INSULIN SENSITIVITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0033861067     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.23.8.1154     Document Type: Article

References (39)

1. Pathogenesis of type 2 diabetes: Metabolic and molecular implications for identifying diabetes genes
2. The prevention and treatment of obesity: Application to type 2 diabetes
3. The metabolically obese, normal weight individual
4. Physical and metabolic characteristics of persons with diabetes
5. The thrifty genotype in non-insulin dependent diabetes mellitus
6. Fat, energy and mammalian survival
7. Circadian rhythms regulate the expression of the thrifty genotype/phenotype
8. Circadian neuroendocrine role in age-related changes in body fat stores and insulin sensitivity of the male Sprague-Dawley rat
9. Bromocriptine induced reduction of body fat in pigs
10. Ergot compounds and brain function: Neuroendocrine and neuropsychiatric aspects
11. Bromocriptine inhibits the seasonally occurring obesity, hyperinsulinemia, insulin resistance and impaired glucose tolerance in the Syrian hamster, Mesoricetus auratus
12. Bromocriptine alters hormone rhythms and lipid metabolism in swine
13. Bromocriptine redirects metabolism and prevents seasonal onset of obese hyperinsulinemic state in Syrian hamsters
14. Intracerebroventricular administration of bromocriptine ameliorates the insulin resistant/glucose intolerant state in hamsters
15. Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects
16. Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemic women
17. Timed bromocriptine administration reduces body fat stores in obese subjects and hyperglycemia in type II diabetics
18. Nutritional recommendations and principles for people with diabetes mellitus
19. Effect of insulin on the distribution and disposition of glucose in man: Insights from physiologic modeling
20. Glucose clamp technique: A method for quantifying insulin secretion and resistance
21. Measurement of abdominal fat with T1-weighted MR images
22. Effect of sustained physiologic hyperinsulinaemia and hyperglycaemia on insulin secretion and insulin sensitivity in man
23. Influences of glucose loading and of injected insulin on hepatic glucose output
24. Glucoregulatory responses in normal and diabetic dogs recorded by a new tracer method
25. Indirect calorimetry: Methodological and interpretative problems
26. 13C nuclear magnetic resonance spectroscopy
27. Densitrometric analysis of body composition: Revision of some quantitative assumptions
28. Effects of weight loss on glucose homeostasis in NIDDM
29. Central obesity: Measurement and metabolic effects
30. Bromocriptine (Ergoset) reduces body fat, hyperinsulinemia, and glucose intolerance in obese subjects
31. Ergoset as monotherapy improves glycemic control in obese NIDDM subjects
32. Effect of insulin on oxidative and non-oxidative pathways of glucose and FFA metabolism in NIDDM: Evidence for multiple sites of insulin resistance
33. The disposal of an oral glucose load in healthy subjects: A quantitative study
34. Bromocriptine inhibits in vivo free fatty acid oxidation and hepatic glucose output in seasonally obese hamsters, Mesocricetus auratus
35. Bromocriptine reduces obesity, glucose intolerance and extracellular monamine metabolite levels in the ventromedial hypothalamus of Syrian hamsters
36. The disposal of an oral glucose load in patients with non-insulin dependent diabetes
37. Regulation of splanchnic and peripheral glucose uptake by insulin and hyperglycemia